-+ 0.00%
-+ 0.00%
-+ 0.00%

UCB And Biogen Present Broad Clinical Efficacy Of Dapirolizumab Pego In Moderate-To-Severe Systemic Lupus Erythematosus At EULAR

Benzinga·06/12/2025 05:45:14
Listen to the news
  • Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity
  • DZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE)
  • At Week 48, more individuals receiving DZP experienced no or low disease activity compared to standard of care with differences observed as early as Week 12